Shattuck Labs Announces Exercise of Outstanding Common Stock Warrants and Provides Financial Update
Rhea-AI Summary
Shattuck Labs (NASDAQ: STTK) reported that holders have exercised or given notices to exercise approximately 50.6 million common stock warrants, about 96% of warrants issued in the August 4, 2025 private placement. This is expected to generate roughly $54.9 million in gross proceeds, including $5.6 million received by March 31, 2026 and an additional $49.3 million anticipated. Combined with $90.4 million in cash, cash equivalents and short-term investments as of March 31, 2026, Shattuck expects to fund operations into 2029, based on current plans.
Positive
- Approximately 50.6 million warrants exercised, representing about 96% of August 2025 issuance
- Total gross proceeds from warrant exercises expected to be about $54.9 million
- Cash, equivalents and short-term investments were about $90.4 million as of March 31, 2026
- Company expects existing cash plus warrant proceeds to fund operations into 2029
Negative
- Exercise of roughly 50.6 million common stock warrants increases share count and potential shareholder dilution
News Market Reaction – STTK
In the Jun 9 session, STTK gained 9.49%, reflecting a notable positive market reaction. Argus tracked a peak move of +12.7% during that session. Argus tracked a trough of -14.0% from its starting point during tracking. Our momentum scanner triggered 19 alerts that day, indicating notable trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jun 08 | Clinical data update | Positive | -13.5% | Phase 1 SL-325 data in 72 volunteers showed favorable safety and target engagement. |
| Jun 05 | Investor event announcement | Neutral | -13.5% | Announcement of June 8 investor call to review SL-325 Phase 1 data and pipeline. |
| May 07 | Earnings update | Positive | -6.3% | Q1 2026 results with cash at $90.4M and runway into 2029 assuming warrant exercise. |
| Mar 05 | Earnings results | Positive | +7.8% | FY 2025 report showing higher cash, reduced R&D spend, and improved annual net loss. |
| Feb 25 | Conference participation | Neutral | -5.4% | Planned presentations at March healthcare investor conferences and related one-on-one meetings. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent history shows frequent negative price reactions, even to positive clinical and financial updates, with only one clear alignment on earnings out of the last five events.
Over the past few months, Shattuck has focused on its DR3-blocking antibody SL-325 and strengthening its balance sheet. Phase 1 data in 72 volunteers looked favorable, with progression toward a Phase 2 Crohn’s trial, yet shares fell 13.54% around that update. Q1 2026 results showed cash rising to $90.4M and an expected runway into 2029, but the stock still declined. Today’s warrant-exercise driven cash update fits this ongoing theme of cautious market reception.
Key Terms
warrants financial
private placement financial
gross proceeds financial
monoclonal medical
bispecific medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
AUSTIN, Texas and DURHAM, N.C., June 09, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of potentially first-in-class monoclonal and bispecific DR3-blocking antibodies for the treatment of patients with inflammatory and immune-mediated diseases, today announced it has received notices to exercise totaling approximately 50.6 million common stock warrants to date, representing approximately
About Shattuck Labs, Inc.
Shattuck Labs, Inc. is a clinical-stage biotechnology company pioneering the development of potentially first-in-class monoclonal and bispecific DR3 blocking antibodies for the treatment of patients with inflammatory and immune-mediated diseases. Shattuck’s expertise in protein engineering and the development of novel TNF receptor therapeutics come together in its lead program, SL-325, a potentially first-in-class DR3 antagonist antibody designed to achieve a more complete blockade of the clinically validated DR3/TL1A pathway. The Company has offices in both Austin, Texas and Durham, North Carolina. For more information, please visit: www.ShattuckLabs.com.
Forward-Looking Statements
Certain statements in this press release may constitute “forward-looking statements” within the meaning of the federal securities laws, including, but not limited to, Shattuck’s expectations regarding: plans for its preclinical studies, clinical trials and research and development programs, particularly with respect to SL-325; the anticipated timing of initiation of a Phase 2 clinical trial of SL-325 in patients with Crohn’s disease; the clinical benefit, safety and tolerability of SL-325; anticipated development of additional preclinical pipeline candidates; the timing of nomination, release of preclinical data and development timelines of a lead bispecific antibody candidate; and expectations regarding the time period over which the Company’s capital resources will be sufficient to fund its anticipated operations. Words such as “may,” “might,” “will,” “objective,” “intend,” “should,” “could,” “can,” “would,” “expect,” “believe,” “design,” “estimate,” “predict,” “potential,” “develop,” “plan” or the negative of these terms, and similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to it on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties (including, without limitation, those set forth in Shattuck’s filings with the U.S. Securities and Exchange Commission (SEC)), many of which are beyond its control and subject to change. Actual results could be materially different. Risks and uncertainties include: global macroeconomic conditions and related volatility; expectations regarding the initiation, progress, and expected results of the Company’s preclinical studies, clinical trials and research and development programs; expectations regarding the timing, completion and outcome of the Company’s preclinical studies and clinical trials; the unpredictable relationship between preclinical study results and clinical study results; the timing or likelihood of regulatory filings and approvals; liquidity and capital resources, including the time period over which current capital resources are expected to the fund the Company’s operations; and other risks and uncertainties identified in Shattuck’s Annual Report on Form 10-K for the year ended December 31, 2025, and subsequent disclosure documents filed with the SEC. Shattuck claims the protection of the Safe Harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements. The Company expressly disclaims any intention to update or alter any statements whether as a result of new information, future events or otherwise, except as required by law.
The Company intends to use the investor relations portion of its website as a means of disclosing material non-public information and for complying with disclosure obligations under Regulation FD.
Investor & Media Contact:
Andrew R. Neill
Chief Financial Officer
Shattuck Labs, Inc.
InvestorRelations@shattucklabs.com
